Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Naomi Sinclair"'
Autor:
Helen R. Davies, Kirsty Hodgson, Edward Schwalbe, Jonathan Coxhead, Naomi Sinclair, Xueqing Zou, Simon Cockell, Akhtar Husain, Serena Nik-Zainal, Neil Rajan
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
CYLD cutaneous syndrome (also known as Brooke-Spiegler syndrome) is characterised by germline mutations in the tumor suppressor CYLD. Here, the authors highlight recurrent mutations in DNMT3A and BCOR, indicating a role for epigenetic dysregulation i
Externí odkaz:
https://doaj.org/article/455161ea0e7d48609e0545f51dafe8d6
Autor:
Naomi Sinclair, Simon Cockell, Helen Davies, Kirsty Hodgson, Neil Rajan, Edward C. Schwalbe, A. Husain, Xueqing Zou, Serena Nik-Zainal, Jonathan Coxhead
Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes 1,2. We comprehensively profiled the genomic landscape of 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e21c24787f62458f81c3271ca3c6382
Autor:
Marina, Danilenko, Elaine, Stamp, Deborah D, Stocken, Akhtar, Husain, Monique, Zangarini, Amy, Cranston, Robert, Stones, Naomi, Sinclair, Kirsty, Hodgson, Susan A, Bowett, David, Roblin, Silvio, Traversa, Ruth, Plummer, Gareth, Veal, James A A, Langtry, Alan, Ashworth, John, Burn, Neil, Rajan
Publikováno v:
JAMA Dermatology
Key Points Question Can targeting tropomyosin receptor kinase with an existing topical kinase inhibitor, pegcantratinib, 0.5% (wt/wt), reduce cutaneous cylindroma tumor volume more than placebo? Findings In this phase 2 clinical trial that included 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::162ad5572e6966e5a9ed58689c41efa0
https://pubmed.ncbi.nlm.nih.gov/29955768
https://pubmed.ncbi.nlm.nih.gov/29955768
Autor:
Edward C. Schwalbe, X. Zou, Kirsty Hodgson, Jonathan Coxhead, Naomi Sinclair, S. Nik-Zainal, Neil Rajan, Simon Cockell, H. Davies, A. Husain
Publikováno v:
Journal of Investigative Dermatology. 139:S262
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64762a0c07eeb27bf36227dfca53d67a
https://doi.org/10.1016/j.jid.2019.07.278
https://doi.org/10.1016/j.jid.2019.07.278
Autor:
Neil, Rajan, Richard J R, Elliott, Alice, Smith, Naomi, Sinclair, Sally, Swift, Christopher J, Lord, Alan, Ashworth
Publikováno v:
Oncotarget
CYLD, an ubiquitin hydrolase, has an expanding repertoire of regulatory roles in cell signalling and is dysregulated in a number of cancers. To dissect CYLD function we used a proteomics approach to identify CYLD interacting proteins and identified M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a036c7aeccb15f9416389bad6c8eed5d
https://pubmed.ncbi.nlm.nih.gov/25565632
https://pubmed.ncbi.nlm.nih.gov/25565632
Autor:
Naomi Sinclair, Neil Rajan, Amanda Smith, Sally Swift, Richard Elliott, Christopher J. Lord, Alan Ashworth
Publikováno v:
Journal of Investigative Dermatology. :S53-S63
// Neil Rajan 1, 2, * , Richard J.R. Elliott 1, * , Alice Smith 1 , Naomi Sinclair 2 , Sally Swift 1 , Christopher J. Lord 1 , Alan Ashworth 1 1 The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341f96dc381a700930fdc8eadce071ac